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ABSTRACT 
 
POTES, C.S. and T.A. LUTZ. Brainstem mechanisms of amylin induced anorexia. PHYSIOL 
BEHAV 00(0) 000-000, 2010.-Amylin is secreted by pancreatic beta-cells and is believed to 
be a physiological signal of satiation. Amylin’s effect on eating has been shown to be 
mediated via a direct action at the area postrema (AP) via amylin receptors that are 
heterodimers of the calcitonin receptor core protein with a receptor activity modifying protein. 
Peripheral amylin leads to accumulation of cyclic guanosine monophosphate, phosphorylated 
extracellular-signal regulated kinase 1/2 and c-Fos protein in AP neurons. The particular 
amylin activated AP neurons mediating its anorexigenic action seem to be noradrenergic. The 
central pathways mediating amylin’s effects have been characterized by lesioning and tracing 
studies, identifying important connections from the AP to the nucleus of the solitary tract and 
lateral parabrachial nucleus. Amylin was shown to interact, probably at the brainstem, with 
other signals involved in the short term control of food intake, namely cholecystokinin, 
glucagon-like peptide 1 and peptide YY. Amylin also interacts with the adiposity signal 
leptin; this interaction, which is thought to involve the hypothalamus, may have important 
implications for the development of new and improved hormonal obesity treatments. 
In conclusion, amylin actions on food intake seem to reside primarily within the brainstem, 
and the associated mechanisms are starting to be unraveled. 
 
 
KEYWORDS: amylin, anorexia, brainstem, pathway, area postrema, noradrenergic neurons, 
cholecystokinin, phosphorylated ERK, cGMP, c-Fos, food intake, body weight 
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INTRODUCTION 
 
Characterization of amylin’s effect on eating 
Amylin, also known as islet amyloid polypeptide (IAPP), is a 37 amino acid peptide from the 
calcitonin gene related peptide family [1]. Amylin is co-secreted with insulin by pancreatic β-
cells in response to nutrient ingestion at a ratio of about 1:100 (amylin:insulin)[2,3]. Amylin 
has a short half-life of about 15 min in blood circulation [4].  
In rats, food intake (e.g. a 5 g test meal given to overnight fasted rats) results in a rapid 
increase in the endogenous plasma amylin concentration from a fasting level of approximately 
3 pmol/l to postprandial levels of about 15-20 pmol/l measured in aortal blood [5]. This 
increase in plasma amylin was subsequently shown to correlate with the size of the respective 
meal [5]. Acute intraperitoneal (IP) injections of 1-100µg/kg amylin decrease eating in rats 
within few minutes, and dose-dependently reduce meal size without producing signs of 
visceral illness [6-8]. Intravenous (3-4h: 600–2000 pmol . kg-1 . min-1) and intra-area postrema 
(30 µg over 3h) administration of the amylin receptor antagonist AC187, at doses that block 
the eating-inhibitory effect of exogenous amylin, stimulates eating by increasing meal size 
[9,10]. The lowest dose of exogenous amylin able to produce a significant reduction in 
feeding yields plasma amylin levels which are only slightly higher than the concentrations 
measured postprandially [5,11]. For these and other reasons, it is generally believed that 
amylin fulfils the criteria of a physiological signal of satiation [12,13]. This action seems to be 
primarily mediated by the area postrema (AP) in the hindbrain (see section 1 below). 
Chronic amylin administration via minipump (2 µg/kg/h, IP) leads to a sustained reduction in 
food intake due to a decrease in average meal size which is not compensated by an increase in 
meal frequency [14]. Subsequently, chronic amylin leads to a reduction in body weight gain 
in rats [7,14]. These findings reported in laboratory rodents have corresponding effects under 
clinical conditions in humans. The amylin analogue pramlintide (120-240µg, 3 times/day) 
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causes weight loss in obese subjects starting 2 weeks after the onset of treatment; this weight 
loss is accompanied by sustained reductions in portion size, in 24h food intake, and also in 
binge eating tendencies [15,16]. Long term treatment for 16 weeks resulted in a marked 
reduction in body weight that remained significantly lower even 8 weeks after treatment 
cessation [15]. 
The role of endogenous amylin in the control of eating has also been investigated using 
amylin knockout (KO) mice. Most studies using these mice showed no difference in adult (≥4 
months) body weight compared with wildtype (WT) animals [17-19]. However, amylin KO 
mice showed a higher rate of body weight gain than WT controls, between one and about 4 
months of age [18,20]. Average food intake in amylin KO mice was shown to be slightly 
though not significantly higher than in WT animals during this time window, but food intake 
was only measured on specific days (about once weekly), and not throughout the entire time 
window from weaning to 4 months of age [19,21]. 
Rats transgenic for the overexpression of human amylin had a slightly lower body weight than 
WT controls [22]. This is in principle consistent with the reported effects of exogenous 
amylin on eating and body weight gain, but food intake in these rats was not measured 
systematically. 
 
Other effects of amylin 
Amylin seems to exert additional effects at physiological plasma concentrations, such as 
inhibition of gastric emptying, glucagon secretion, and of gastric acid and digestive enzyme 
secretion [12,21]. The former two effects are the basis for the use of pramlintide in co-therapy 
with insulin in diabetic humans because it improves blood glucose profiles in type 1 and type 
2 diabetes mellitus patients [23,24]. From the above mentioned actions, the AP was shown to 
mediate amylin’s action to inhibit gastric emptying, eventually involving vagal efferents 
[25,26]. The site(s) of action for the other effects still need further investigation. 
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Both acute and chronic administration of amylin and of the amylin receptor agonist salmon 
calcitonin (sCT) increase energy expenditure, as assessed by indirect calorimetry [7,27-30]. 
For a review on the effects of exogenous amylin on energy expenditure see [31]. The 
physiological role of amylin’s effect on energy expenditure and the exact site of action are 
still unclear. One of our own unpublished studies suggests that this effect is also mediated by 
the AP because direct low dose amylin or sCT infusions into the AP increased energy 
expenditure and body temperature, but these findings still require confirmation. Several lines 
of evidence indicate that amylin may also share characteristics of adiposity signals, such as 
leptin or insulin. This aspect of amylin action is extensively covered in a recent review [32]. It 
is not clear whether the same hindbrain neuromechanisms involved in amylin’s satiating 
effect are involved in that latter aspect of amylin action. 
 
1 - Amylin site of action at the brainstem 
The AP is one of several brain regions that show strong amylin binding in amylin receptor 
autoradiography studies [33]. The anorectic effect of amylin seems to be mediated by a direct 
humoral action on neurons in the AP [14,34] which lacks a functional blood brain barrier [35]. 
Next, we list the available structural and functional data indicating that this activation of the 
AP is necessary and sufficient to bring about amylin’s satiating effect. 
The amylin receptor, which is expressed in the AP, is a heterodimer of the type a or type b 
calcitonin receptor (CTR) as a core receptor and one of the known receptor activity modifying 
proteins (RAMP), typically RAMP 1 or 3. RAMPs confer specificity of the CTR to amylin 
[36,37], i.e. they alter CTR pharmacology from calcitonin-preferring to amylin-preferring 
receptors. The RAMPs are believed to regulate the transport of the core receptors to the cell 
surface and their glycosylation state, which determines ligand specificity [38,39]. The CTR is 
densely expressed in the AP [40], and RAMP1 and RAMP3 mRNA have also been 
discovered in the mouse AP [41]. Amylin-induced c-Fos mRNA, CTR(a) and RAMP3 mRNA 
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expression co-localize in the rat AP [42]; further, most AP neurons in which systemic amylin 
specifically induces cyclic guanosine monophosphate (cGMP) formation carry the CTR 
([40,43] and unpublished observation). Despite the clear evidence that all structural 
components of functional amylin receptors are present in the AP, one critical experiment still 
needs to be performed, i.e. an experiment that tests whether the CTR and RAMP1 or RAMP3 
colocalize in the same amylin-sensitive AP neurons. 
These structural data are complemented by independent functional data. The acute eating 
inhibitory effect of amylin was not blocked by either specific hepatic branch vagotomy, by 
total subdiaphragmatic vagotomy or by capsaicin-induced lesions of peripheral neural 
afferents that project to the brain [8,44,45]. However, the effect of both acute and chronic 
amylin administration was abolished in AP lesioned rats [14,34]. Further, local injection of 
small doses of amylin into the AP inhibited eating by reducing meal size, and AP injection of 
the amylin receptor antagonist AC187 not only had the opposite effect when given alone, but 
also blocked the anorectic effect of exogenous peripheral amylin [10]. 
The behavioral data are consistent with immunohistochemical and electrophysiological 
studies, in which amylin exerted direct excitatory effects in the AP [43,46]. It is believed that 
the AP also mediates amylin’s action to inhibit gastric emptying, which may require vagal 
efferents [25,26,47]. 
 
AP neurons are also sensitive to nutrients 
Electrophysiological studies have shown that amylin and glucose co-activate AP neurons 
[48]. This seems to have some functional correlate because amylin’s effect to reduce the rate 
of gastric emptying is not present under hypoglycemic conditions. This phenomenon was 
considered a fail-safe mechanism to allow appropriate supply of nutrients at a time when they 
are urgently needed [49]. It is unknown at present if the anorectic effect of amylin is also 
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affected by hypoglycemia in the same way, i.e. whether amylin reduces eating under 
euglycemic and hyperglycemic, but not under hypoglycemic conditions. 
Recent findings indicate that the action of amylin on AP neurons may be affected by protein. 
A low dose of peripheral amylin (5 g/kg) induced a strong c-Fos expression in the AP and 
NTS of 24h-fasted rats, but not in rats fed ad libitum [50]. Similar to fasted rats, the same 
amylin dose also induced a strong c-Fos response in rats that received a nutrient-deficient 
non-caloric mash (NCM) for 24 hours before injection. Because selective supplementation of 
NCM with protein, but not with glucose or fat (lard), attenuated the amylin induced c-Fos 
expression observed in NCM fed rats [50], we concluded that protein - or perhaps single 
amino acids - was responsible to attenuate the amylin-induced c-Fos response in the AP. 
Consistent with this view, intraperitoneal injection of an amino acid mixture also significantly 
attenuated the amylin-induced c-Fos expression in the AP in fasted rats [51]. Finally, amylin’s 
anorectic action was stronger in rats fed a 1% protein diet (1% weight/weight) compared to its 
action in rats fed an isocaloric diet with higher protein percentage (8-18%) [51]. The exact 
mechanisms that are responsible for these phenomena still need to be investigated. It needs to 
be tested whether specific amino acids reduce the effect of amylin to activate AP neurons or 
whether the effect is indirect, e.g. by a protein-induced specific release of some hormone that 
in part counteracts amylin action in the AP. Our findings indicate that diet derived protein 
(and amino acids) attenuates amylin’s anorectic action and that this depends on the amount of 
protein itself rather than the caloric intake. The functional implications of these findings, and 
in particular their clinical relevance for the use of the amylin analogue pramlintide in the 
treatment of obesity, need to be defined. 
 
2 - Brainstem intracellular mechanisms mediating amylin signaling 
Numerous studies investigated the central mechanisms that may mediate amylin’s effect on 
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eating. Here, we review specific intracellular signaling molecules in neurons of discrete brain 
areas that are triggered by the peripheral administration of amylin. These molecules will be 
briefly described in this section, as well as the potential functional relevance in respect to 
amylin’s effect on eating. 
Most studies mapping the brain areas activated by amylin made use of the expression pattern 
of the immediate early gene product c-Fos by immunohistochemistry. Such studies were 
extremely useful in delineating the general central nervous system pathways that are activated 
by peripheral amylin. They showed that in addition to the AP, the neuroaxis mediating amylin 
action also comprises the nucleus of the solitary tract (NTS) and the lateral parabrachial 
nucleus (LPB) [46,52,53]. 
Immunohistological studies have shown that exogenous and endogenous amylin activate the 
same brain structures. Refeeding, i.e. 2h-access to food after a 24h-food deprivation period, 
caused substantial neuronal activation in the AP and NTS comparable to that of exogenous 
amylin [46], and this response in the AP was blocked by the amylin receptor antagonist 
AC187 [46]. This suggested that the feeding induced release of endogenous amylin 
contributes to the AP neuronal activation in refed animals. 
Despite its widespread use, the mapping of activated brain areas using c-Fos protein 
expression has several downsides compared with other techniques. Most importantly, the 
functional role of amylin-induced c-Fos formation is completely unclear. The eating 
inhibitory effect of acute amylin occurs within few minutes after administration while c-Fos-
protein expression typically starts at 30 min and reaches its peak 60-120 min after the 
stimulus [46,52,54,55], hence at a time long after the acute eating inhibitory effect of amylin 
is fully developed. Further, in contrast for example to real time functional imaging techniques 
that provide time resolution and show both inhibitory and excitatory events, c-Fos 
immunohistochemistry reflects only one specific time point after a given stimulus, and it 
cannot identify areas that are inhibited by amylin. Overall, the functional implications of c-
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Fos expression in relation to amylin’s anorectic action are unknown and both effects can in 
fact be dissociated under some experimental conditions. One piece of evidence is that 5 g/kg 
of amylin administered subcutaneously in fed rats only induced a very low number of c-Fos-
positive nuclei, but the same or lower doses induced a significant anorectic action to a similar 
degree as in previously fasted rats [6,50]. 
Immunohistological and electrophysiological studies indicate that amylin exerts excitatory 
effects in AP neurons that are mediated by an increased formation of the intracellular second 
messenger cyclic guanosine monophosphate (cGMP) [43]. In contrast to c-Fos expression, 
formation of cGMP may be functionally involved in amylin’s eating inhibitory effect because 
local AP injection of a membrane permeable analogue of cGMP also decreased eating by a 
meal size effect [10]. Whether local blockade of cGMP formation in the AP ablates the eating 
inhibitory effect of amylin has not been tested. 
Recently, the extracellular-signal regulated kinase 1 and 2 (ERK 1/2) cascade, one of the four 
members of the mitogen-activated protein kinase family, was also identified as one possible 
intracellular second messenger system to bring about amylin’s effect in AP neurons. The 
ERK1/2 cascade is a highly conserved signaling pathway involved in various cellular 
processes [56,57]. Activation of this pathway leads to a rapid ERK1/2 phosphorylation and 
subsequent activation of gene transcription; importantly, it also leads to acute neuronal 
responses such as activation or inhibition of ion channels that directly affect neuronal 
excitability [58,59]. Hence, the ability for the ERK cascade to be quickly activated and 
deactivated, and its direct involvement in fast neuronal responses of ion channel modulation, 
makes it an interesting candidate signaling system for the study of many behaviors. In other 
words, in contrast to c-Fos expression, it is plausible that the ERK pathway may be 
functionally involved in fast eating inhibitory effects. Consistent with this idea, it had 
previously been demonstrated that the ERK pathway is activated in the NTS in response to 
administration of peripheral cholecystokinin (CCK) and that the anorectic action of CCK 
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seems to critically depend on this pathway because a pharmacological blockade of ERK 
phosphorylation attenuated CCK’s immediate anorectic response [60]. The NTS is a site of 
convergence for a variety of anorectic signals including amylin, which may modulate CCK’s 
anorectic effect via the AP/NTS region [19,61]. For this reason and because amylin has 
recently been demonstrated to stimulate ERK signaling in osteoclasts which carry specific 
amylin receptors [17,62], we hypothesized that amylin may also activate this signaling 
pathway in the brainstem, specifically in the AP. In fact, recent studies indicated that amylin 
induces ERK phosphorylation in the AP (Figure 1). Importantly, while we believe that c-Fos 
is probably not directly involved in the anorectic effect of acute amylin, it seems plausible 
that pERK formation may have functional implications. The peak of pERK was observed 
between 10 and 15 min after peripheral amylin (unpublished observation), which is at a time 
when amylin’s satiating effect has been shown previously to be fully developed [6]. A strong 
pERK stimulation was observed even after a low anorectic dose of amylin (mean number of 
pERK positive cells 15min after injection - saline: 1.9  0.4, n=6; 5g/kg amylin: 23.1  2.4, 
n=5; p<0.0001 by t-test; Figure 1). Despite these interesting and promising findings, many 
questions remain unanswered at present. It is e.g. unknown whether pERK formation is 
necessary or sufficient for amylin anorectic action and whether amylin-induced cGMP 
formation [43] is linked to pERK formation. Further, whether the neurons displaying 
phosphorylated ERK after amylin are identical to the neurons expressing c-Fos, and whether 
c-Fos expression is dependent on the ERK cascade activation, are also issues that need to be 
addressed. The functional role of ERK cascade activation on amylin’s anorectic effect is 
currently under evaluation. 
 
3- Brainstem neurotransmitter systems mediating amylin anorexia 
Recent experiments focused on the phenotype of the neurons mediating amylin’s action in the 
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AP. Previous immunohistochemical studies had identified catecholamine and serotonin (5-
HT) immunoreactive fibers and cell bodies in the AP and the NTS [63-65]. The 
catecholaminergic population of neurons in the AP seems to be mainly noradrenergic [63,66]. 
Furthermore, a large number of projections from the AP and NTS to the LPB are 
noradrenergic [67] or serotoninergic [68]. Interestingly, about 20% of AP noradrenergic 
neurons contain also 5-HT, and about 40% of these show projections to the parabrachial 
nucleus [69]. 
Our recent immunohistochemical studies indicate that neurons of these phenotypes are 
specifically activated by amylin. Neurons in the AP that displayed amylin induced c-Fos 
expression showed a marked overlap with cells expressing tyrosine hydroxylase (TH) [70], 
the rate-limiting enzyme in catecholamine synthesis. Subsequent studies indicate that a high 
percentage of these neurons are in fact noradrenergic [71] because they express dopamine-
beta-hydroxylase (DBH), the key enzyme involved in the conversion of dopamine to 
noradrenaline (NA) [63,72]. A smaller percentage of amylin-activated AP neurons expressed 
5-HT and CCK ([71]; and unpublished observation). 
Subsequent behavioral studies clearly implicated NA in mediating amylin’s anorectic effects 
([73]; [74] submitted manuscript); based on the immunohistochemical data, we hypothesized 
that amylin’s ability to reduce food intake and to induce neuronal activation within the AP 
and NTS would be attenuated in the absence of AP NA-neurons. To assess the role of NA-
neurons in the AP, we lesioned AP noradrenergic neurons with the neurotoxin saporin 
conjugated to an antibody against DBH (DSAP). This technique produces a lesion of AP 
neurons that is far more specific than the previously used AP lesioning techniques, e.g. 
thermal ablation or suction [14,34]. That is because using the saporin approach only a specific 
population of neurons is lesioned, leaving the other neurons intact. In fact, amylin induced 
anorexia was observed in sham-lesioned rats but not in rats with a partial DSAP induced 
lesion of the AP NA-neurons. A lesion of 50-60% of the AP noradrenergic population was 
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sufficient to abolish amylin’s anorexigenic effect ([73]; [74] submitted manuscript). In 
contrast to sham-lesioned animals, NA-lesioned rats also displayed an attenuated amylin-
induced c-Fos expression in the AP and NTS. Taken together, these results provide evidence 
for an important and necessary functional role of NA neurons in the AP in the mediation of 
amylin's anorectic effect. 
Some of our previous studies had suggested that the dopaminergic system may mediate part 
of amylin’s inhibitory effect on feeding. Intraperitoneal administration of the dopamine (DA) 
D2-receptor antagonists raclopride or sulpiride, but not of the D1-receptor antagonist SCH-
23390, significantly attenuated amylin’s satiating effect in rats fed a medium fat diet [75]. 
Later we suggested that the pertinent D2-receptors may be involved in signal transmission 
from the AP to the NTS because local infusion of raclopride (10 µg/rat) into the AP/NTS 
region abolished peripheral amylin's effect [70]. Such way of action seems plausible because 
the NTS region contains DA binding sites [76] of the D2 receptor subtype [77]. 
Hence, while these last observations suggest but do not prove a role for D2 receptors in the 
hindbrain, probably in the NTS, in mediating amylin’s anorectic effect, the results need to be 
reconciled with the findings reported above because catecholaminergic AP neurons seem to 
contain mainly NA as their main neurotransmitter [63,72,78]. One cannot rule out that the AP 
NA-neurons also release DA to some extent, or even co-release NA and DA, as it is observed 
under particular conditions in other brain areas such as the cortex [79-81]. Because it seems 
impossible to lesion DA neurons specifically without affecting NA neurons, it remains 
unclear whether the D2 receptors mediate amylin’s effects in the NTS, independent of NA 
signaling. Finally, we cannot exclude that the central injections of raclopride, at the dose used, 
also unspecifically blocked other receptors, namely adrenergic receptors. 
Interestingly, CCK's anorectic action, which at least partly depends on endogenous amylin, 
also involves dopaminergic transmission in this brain region. That is, D2 receptors co-
distribute with CCK-binding sites in the NTS [77], the DA-receptor antagonist cis-flupentixol 
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was able to reduce CCK’s anorectic effect [82] and CCK increased DA tonic levels in the 
NTS [83]. Therefore, we can speculate that the dopaminergic system may specifically be 
involved in integrating CCK and amylin signaling [70], but this still needs to be tested. 
In contrast to noradrenergic AP neurons, the functional role of other amylin activated neurons 
such as serotoninergic cells is unclear. It seems that they are not necessary for amylin’s 
inhibitory effect of eating because general pharmacological blockade of the serotonergic 
system did not affect the amylin induced reduction in feeding [84]. Whether other AP 
mediated functions of amylin depend on serotoninergic AP neurons has not yet been tested. 
Further, the functional role of amylin-activated AP neurons that express CCK (unpublished 
observation) still needs to be defined. 
Finally, we aimed to define the phenotype of amylin-activated second order neurons in the 
NTS by immunohistochemistry. Specifically, we investigated whether amylin-activated c-Fos 
positive NTS neurons co-express TH or glucagon-like peptide 1 (GLP-1). Interestingly, we 
found no such overlap after peripheral amylin injection (Figure 2), so that the phenotype of 
amylin-activated neurons in the NTS remains unknown. 
Histamine was also shown to be functionally involved in the modulation of amylin anorectic 
action, but this effect seems to be mediated by the hypothalamus rather than the brainstem, 
particularly via histamine-1-receptors (H1R) of the ventromedial hypothalamic nucleus 
[85,86]. 
To summarize, so far only the NA system of the AP was confirmed to be functionally 
involved in mediating amylin’s anorectic action via brainstem mechanisms; no such role was 
defined for the other neurotransmitter systems studied so far. 
 
4 - Brainstem neuronal pathways involved in amylin signaling 
Immunohistochemical studies using the immediate early gene product c-Fos as a marker of 
neuronal activation helped to identify the central nervous system activation pattern of amylin. 
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Exogenous and endogenous amylin activate the AP-NTS-LPB neuroaxis, but c-Fos was also 
expressed in the central amygdaloid nucleus (Ce) and the lateral subdivisions of the bed 
nucleus of the stria terminalis (BSTL) [46,52]. These brain structures are part of the central 
gustatory/enteroceptive systems and are mutually interconnected and linked to the 
hypothalamus, the main integrative centre for the control of energy balance [87]. Targeted 
lesions indicate that the AP, the adjacent NTS and the LPB are necessary for amylin’s 
anorectic effect [14,34,53]. These studies also indicate that the pathway involved in 
transmitting amylin’s excitatory signal from the AP to other activated areas require a primary 
action in the AP [46,53,88]. The most important findings are briefly summarized here. 
Lesions of the AP blocked the eating-inhibitory effect of peripheral amylin and the amylin-
induced c-Fos expression in brain areas rostral to the site of lesion, i.e. in the NTS, LPB and 
the Ce [14,34,46,88]. Rats with LPB lesions also displayed a significantly reduced eating-
inhibitory effect of amylin and a marked reduction in the number of c-Fos-positive neurons in 
the Ce, while the level of amylin-induced c-Fos-expression in the AP and NTS remained 
unaltered. This indicates that a LPB lesion specifically blocks the signal transmission from the 
hindbrain to the forebrain, and that this transmission is necessary for amylin’s effect on eating 
[53]. 
Neuronal retrograde and anterograde tracing studies confirmed direct links between these 
amylin-activated areas. We showed that the amylin signal may either be directly transmitted 
from the AP to the LPB or indirectly via the NTS, because dense projections were observed 
from both areas ([89]; [90] submitted manuscript). The LPB also appears to act as an 
important relay station between the hindbrain and the rostro-dorsal lateral hypothalamic area 
(dLHA), where amylin reduces the fasting-induced c-Fos expression [46,89]. Amylin partly 
reversed the fasting-induced dLHA activation [46], and it seems plausible that this inhibition 
may be involved in amylin’s action to reduce food intake. Because the entire LHA is devoid 
of amylin binding sites [33,91,92], we believe that the dLHA most probably receives an 
 15 
indirect amylin-dependent inhibitory input from brainstem amylin-activated areas. The LPB, 
and to a lesser extent the NTS, seem to be the main candidates in providing the amylin 
inhibitory input to the dLHA ([89]; [90] submitted manuscript). Whether this input is 
necessary for amylin’s eating-inhibitory effect requires further studies. 
Interestingly, our tracing studies suggest that the amylin activated pathway also projects to the 
arcuate (Arc) and ventromedial hypothalamic (VMH) nuclei. These brain regions have 
received increased interest lately because they are candidate areas where amylin may interact 
with leptin (see also section 5 below). The functional interaction between amylin and leptin 
may depend on polysynaptic connections from the AP to the VMH and Arc [93,94]. Our 
tracing studies that identified dense projections from the amylin activated LPB to these 
hypothalamic areas are consistent with such a mechanism [89]. 
 
5 - Possible hormone interactions at the brainstem / perspectives 
Because of the potential implications of combined hormonal treatment for anti-obesity 
therapy [95,96], we will briefly discuss the interaction of amylin with other hormones; 
particularly the types of interactions that may involve the brainstem. 
Most of the brainstem areas expressing c-Fos in response to amylin are also activated by other 
gastrointestinal peptides that inhibit eating, namely CCK [97,98], GLP-1 [99] or its receptor 
agonist exendin-4 [100] and peptide YY 3-36 (PYY) [101]. 
As said above, the NTS is a site of convergence for a variety of anorectic signals, possibly 
including amylin and CCK. Because amylin is a necessary modulator of CCK’s anorectic 
action [19,21,61], it has been hypothesized that this interaction may take place at the NTS. 
The potential involvement of dopamine receptors in this respect has been mentioned above in 
section 3. However, behavioral experiments testing these hypotheses have yet to be 
performed. 
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Another gastrointestinal hormone of interest is GLP-1. Due to its incretin effect, GLP-1 is a 
potent stimulator of insulin and amylin secretion [102]. In addition, the neuronal activation 
pattern induced by central GLP-1 and peripheral amylin shows a large overlap [52], and both 
peripheral amylin and exendin-4 activate the same hindbrain areas [46,100]. Further, 
peripheral GLP-1 induced c-Fos in the NTS in mice [99]. Based on these findings, we 
originally hypothesized that at least part of the anorectic effect of GLP-1 may be due to the 
release of endogenous amylin, but this hypothesis could not be substantiated when we tried to 
block GLP-1’s anorectic action by amylin antagonism or vice versa (unpublished 
observation). Further, recent studies indicate that in contrast to amylin [44,45], the anorectic 
effect of intraperitoneally administered GLP-1 is mediated by vagal afferents [103]. Hence, 
despite similar central activation patterns, as gauged by c-Fos expression, the primary targets 
of amylin and GLP-1 to induce their eating-inhibitory action may differ. 
Interestingly, it was shown that the combined treatment of rhesus monkeys with the amylin 
receptor agonist sCT and the GLP-1 receptor agonist exendin-4 produced additive anorectic 
effects [104]. This study indicates that combined administration of GLP-1 and amylin reduces 
eating more than either peptide alone; this does however not necessarily indicate that the two 
hormones interact in a way that the action of the one hormone is necessary for the action of 
the other. We have shown previously that AP neurons are co-activated by amylin and GLP-1 
via their respective receptors as demonstrated by electrophysiological studies [105]. However, 
it is important to note that it has not yet been tested whether an intact AP is necessary for the 
anorectic effect of peripheral GLP-1. Second, amylin and GLP-1 may act on the same neurons 
but trigger different and independent intracellular signaling cascades. Finally, it is not clear if 
under physiological conditions, the co-activation of AP neurons by amylin and GLP-1 is due 
to peripheral GLP-1 released from the gastrointestinal tract acting on the AP, or rather due to 
GLP-1 released from GLP-1-ergic NTS neurons that project to the AP. Overall, the exact 
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mechanisms how the combined action of amylin and GLP-1 translates into a stronger 
reduction of eating than either hormone alone, remains to be clarified. 
Recent studies also investigated a functional interaction between amylin and PYY. It has been 
shown that combination therapy of these two hormones in diet-induced obese rats 
synergistically suppressed food intake and had additive effects on body weight reduction 
when given chronically [106]. This is in principle consistent with our own data showing that 
acute PYY (50 g/kg, IP) enhanced the amylin-induced c-Fos expression in the AP and that 
PYY did not activate AP neurons when given alone [107]. These studies suggest a possible 
concerted action of both hormones in controlling food intake, and that their integrated action 
may take place at the AP. However, pertinent feeding experiments still need to be done. 
Finally, there are several papers pointing to the existence of a strong and probably clinically 
relevant amylin-leptin interaction in the control of eating. Both acute and chronic co-
administration of amylin and leptin produce effects on eating or body weight, respectively, 
that exceed the effects induced by either hormone alone [93,108]. This interaction seems to 
involve an effect of amylin on central leptin signaling, while leptin did not enhance the 
amylin-induced activation of AP neurons as gauged by c-Fos expression [94]. Specifically, 
amylin pre-treatment partially restored leptin sensitivity as gauged by the formation of the 
intracellular signaling molecule pSTAT3 in leptin resistant diet-induced obese rats in the 
VMH [93]; chronic amylin treatment for 4 weeks also increased leptin binding in the VMH of 
lean rats, and acute amylin administration amplified leptin signaling in the Arc [94]. Finally, 
the same paper showed that leptin-induced pSTAT3 formation is reduced in the Arc and 
VMN of amylin KO mice. These results suggest that amylin increases leptin sensitivity in 
leptin-sensitive and in leptin-resistant rats; the findings in amylin KO mice further suggest 
that endogenous amylin is involved in the intrinsic neuromechanisms that modulate leptin 
sensitivity. Overall, available evidence indicates that the interaction between amylin and 
leptin may not be a direct hindbrain mechanism, but may depend on a primary amylin action 
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in the AP and polysynaptic connections from the AP, via the LPB, to the VMH and Arc where 
leptin acts [89,93,94]. However, because endogenous leptin signaling in the hindbrain seems 
to be necessary for the physiological control of energy balance [109], further and more 
detailed studies are required to investigate the potential relevance of the hindbrain in the 
amylin/leptin interaction.  
 
6 – Areas of Research 
In this review we summarized the current knowledge on the relevance of the brainstem in the 
mediation of amylin’s anorectic action. Obviously, there is still a long list of unanswered or 
only partly answered questions. These include e.g.: Which specific amylin receptor form is 
expressed in the AP amylin activated neurons? Is cGMP induced specifically in NA-neurons 
in the AP? What is the phenotype of the amylin activated neurons in the AP that do not 
express NA? Are those neurons also relevant for amylin’s effect on eating? Are there amylin 
inhibited brainstem areas? Is the pERK cascade in the AP neurons involved in amylin’s 
anorectic action? Are there specific effects of amylin (e.g. meal size reduction, energy 
expenditure, adiposity signaling…) that can be associated with one specific intracellular 
signaling system (e.g. cGMP, pERK, c-Fos)? Where and how exactly does amylin interact 
with other hormones controlling eating? 
 
CONCLUDING REMARKS 
 
Studies carried out over the last 25 years gathered an extensive array of data on amylin’s 
effect on eating; those findings clearly classify amylin as a physiological satiation signal. The 
characterization of amylin’s site of action, intracellular signaling cascades, neurotransmitters 
and central pathways mediating amylin’s effects on food intake, body weight, and other 
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metabolic effects, has advanced tremendously in recent years. Unlike many other hormones 
which act primarily via the hypothalamus or vagal afferents, amylin’s anorectic action is 
believed to be centered at the brainstem. Our current working model is presented in Figure 3. 
The feeding effect of amylin seems to involve cGMP formation in the AP, and it is believed 
to be transmitted by catecholaminergic neurons of the AP (releasing NA and perhaps DA) to 
the NTS or LPB. From the LPB, the amylin signaling is supposed to be transmitted to 
forebrain areas. The hypothalamic areas that may also be involved in the effect include the 
VMH, where amylin signaling seems to be mediated via H1R; the Arc, which similarly to the 
VMH, seems to be important for the amylin-leptin interaction; and the LHA, where amylin 
attenuates the fasting-induced neuronal activation. 
Further understanding on amylin’s mode of action is fundamental to develop new and more 
efficient therapeutic approaches to treat obesity. 
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FIGURES AND LEGENDS 
 
 
 
 
Figure 1: Amylin induced ERK phosphorylation (pERK) in the area postrema (AP). Animals 
injected subcutaneously with either saline or 5 μg/kg of amylin at dark onset and perfused 15 
minutes later. Labeling of pERK-positive neurons in the AP performed by 
immunohistochemistry against the phosphorylated form of ERK 1/2. Arrows point to 
examples of pERK-positive neurons. 
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Figure 2: Lack of colocalization between amylin induced c-Fos, GLP-1 and tyrosine 
hydroxylase (TH) in the nucleus of the solitary tract. Animal injected intraperitoneally with 5 
μg/kg of amylin at dark onset and perfused 2 hours later. Fluorescent immunohistochemistry 
labeling of c-Fos nuclei in red, GLP-1-positive neurons in green and TH-positive neurons in 
blue color. 
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Figure 3: Summary scheme of the proposed mechanisms involved in amylin’s anorexigenic 
effect; neuronal systems that are triggered by amylin, but for which a function was not yet 
established are also shown. Circulating amylin is proposed to bind to the heterodimer of 
CTR/RAMP (RAMP1 or RAMP3) receptor, and to induce cGMP formation in AP neurons. 
The amylin triggered signal seems to be transmitted by catecholaminergic neurons (that 
produce NA and perhaps DA) projecting to the NTS or LPB. The functional relevance of c-
Fos and pERK formation in the AP, as well as the role of the small amylin activated 5-HT 
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population in the AP, is not known. From the LPB, the amylin signal is probably transmitted 
to hypothalamic areas that may also be involved in amylin’s feeding effect, including the 
VMH, the Arc and the LHA. The amylin excitatory signal from the LPB reaches the Ce and 
BSTL (as characterized by c-Fos-expression), but the functional significance of these 
projections has yet to be established. 3V = third ventricle; CC = central canal; f = fornix; scp 
= superior cerebellar penduncle; sol = solitary tract. 
 
 
